Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum

Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company dedicated to developing treatments for central nervous system (CNS) disorders, has announced its participation in the Stifel 2026 Virtual CNS Forum, scheduled for March 17-18, 2026. Dr. Remy Luthringer, the Executive Chairman and CEO of Minerva, will present on Wednesday, March 18, at 8:30 AM ET. Attendees can view the presentation through a designated webcast link.

The company is currently focusing on advancing its lead product candidate, roluperidone, which is being developed to treat negative symptoms of schizophrenia. This initiative builds on the growing recognition of the need for effective treatments in the area of schizophrenia, particularly addressing symptoms that significantly impact patients' quality of life. Minerva is preparing to initiate a confirmatory Phase 3 trial for roluperidone, a crucial step in the drug development process that could lead to regulatory approval.

As part of the conference, Minerva invites interested parties to arrange virtual meetings with its team. Stakeholders, including investors and analysts, may reach out through their Stifel representatives to schedule discussions for further insights into the company's strategy and developments.

For those unable to attend the live presentation, a replay will be made accessible on Minerva’s Investors & Media section on its website for ninety days post-event. This approach ensures that a broader audience can stay informed about the company’s progress and insights shared during the conference.

Minerva Neurosciences continues to exemplify a commitment to pioneering advancements in treatments for CNS disorders, addressing critical challenges in mental health and striving to improve patient outcomes.

Minerva Neurosciences, Inc. (Nasdaq: NERV) presents a compelling opportunity in the biopharmaceutical sector, especially with its upcoming participation in The Stifel 2026 Virtual CNS Forum. Scheduled for March 18, 2026, CEO Remy Luthringer, PhD, will share insights into the company's ongoing developments, notably their confirmatory Phase 3 trial with roluperidone targeting negative symptoms of schizophrenia.

As a clinical-stage biopharmaceutical company, Minerva is strategically positioned within the CNS disorder therapeutics market—a sector burgeoning due to increasing prevalence and heightened focus on mental health treatment. Investors should keep a close watch on the outcomes of the Phase 3 trial, as its success could significantly influence the company's stock trajectory.

Minerva's roluperidone is pioneering in its approach to address negative symptoms often associated with schizophrenia, which are under-treated and can drastically impact patients' quality of life. If the trial results are favorable, this could not only lead to regulatory approval but also establish Minerva as a noteworthy player within a relatively unexplored market niche, potentially driving up investor confidence and stock value.

Furthermore, the virtual forum presents a valuable opportunity for engagement and information dissemination. Investors are encouraged to participate in virtual meetings offered through their Stifel representatives to gain deeper insights into the company’s strategic direction and product pipeline.

Given the volatile nature of clinical-stage biotech stocks, it would be prudent to monitor corporate communications closely, particularly around key clinical milestones. Robust trial results and strong management communication can catalyze stock price appreciation. As always, consider your risk tolerance and investment strategy before making tactical decisions on Minerva Neurosciences.